Prescient Therapeutics Limited (ASX:PTX)
0.0430
0.00 (0.00%)
Aug 25, 2025, 4:10 PM AEST
Prescient Therapeutics Revenue
In the fiscal year ending June 30, 2025, Prescient Therapeutics had annual revenue of 4.36M AUD with 17.35% growth. Prescient Therapeutics had revenue of 3.11M in the half year ending June 30, 2025, with 164.84% growth.
Revenue
4.36M
Revenue Growth
+17.35%
P/S Ratio
10.27
Revenue / Employee
1.45M
Employees
3
Market Cap
44.73M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 4.36M | 644.03K | 17.35% |
Jun 30, 2024 | 3.71M | 1.28M | 52.89% |
Jun 30, 2023 | 2.43M | 538.79K | 28.52% |
Jun 30, 2022 | 1.89M | 703.86K | 59.37% |
Jun 30, 2021 | 1.19M | 156.14K | 15.17% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 23.73B |
Pro Medicus | 212.98M |
Cochlear | 2.34B |
Sonic Healthcare | 9.65B |
Ramsay Health Care | 17.12B |
Telix Pharmaceuticals | 1.01B |
Ansell | 3.00B |
Mesoblast | 9.16M |